Under the partnership, Sixfold utilized SEDA’s expert knowledge of pharmaceutical development, DMPK and clinical pharmacology to build on their roadmap for advancing their preclinical Mergo® candidates.

The collaboration, funded by the Sustainable Innovation Fund from Innovate UK, also focused on increasing the therapeutic loading capacity of Sixfold’s delivery platform.

Dr Anna Perdrix Rosell, Sixfold Bioscience’s Co-Founder and Managing Director, commented:

“By harnessing SEDA’s expertise in drug development, we have strengthened our preclinical strategy, ensuring streamlined advancement of our RNA-delivery technology.”

Prof Paul Stott, CEO, SEDA Pharm Dev Services commented:

“The combination of the unique innovation created by the Sixfold team with the development experience and expertise from SEDA has helped to create a clear development pathway and take this novel technology one step closer to patients”.

Sixfold Bioscience Ltd.

Sixfold Bioscience is a venture-backed preclinical-stage biotechnology company based at the Innovation and Translation Hub in White City, London. Sixfold develops nucleic acid-based drug delivery systems, with a focus on short interfering RNA for gene silencing and messenger RNA for gene expression. For more information, visit: https://www.sixfold.bio

SEDA

SEDA Pharmaceutical Development Services provide Pharmaceutical Development and Clinical Pharmacology services and consultancy to the Pharma and Biotechnology Industry. We enable the rapid and efficient development of optimal medicinal products by providing coherent and synergistic support. For more information, visit: https://www.sedapds.com/

‍